Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies
暂无分享,去创建一个
G. Colditz | E. Yeoh | S. Tworoger | Z. Ren | Zheqing Zhang | Xuefen Su | Fangfang Zeng | Huishan Wei
[1] F. Camacho,et al. Analgesic medication use and risk of epithelial ovarian cancer in African American women , 2016, British Journal of Cancer.
[2] D. Greenwood,et al. Circulating C-Reactive Protein and Breast Cancer Risk—Systematic Literature Review and Meta-analysis of Prospective Cohort Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[3] I. Gram,et al. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[4] P. Hartge,et al. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. , 2014, Gynecologic oncology.
[5] Ying Zhang,et al. CRP 1059 G/C and 1846G/A polymorphisms and cancer risk: a meta-analysis of 26,634 subjects. , 2014, Clinics and research in hepatology and gastroenterology.
[6] M. Pike,et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. , 2014, Journal of the National Cancer Institute.
[7] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[8] P. Ridker,et al. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer. , 2013, American journal of epidemiology.
[9] S. Friis,et al. Nonsteroidal anti‐inflammatory drugs and risk of ovarian cancer: systematic review and meta‐analysis of observational studies , 2013, Acta obstetricia et gynecologica Scandinavica.
[10] Jacques Ferlay,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .
[11] Xiaolei Zhang,et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. , 2012, Cytokine.
[12] C. Madeddu,et al. Inflammation and ovarian cancer. , 2012, Cytokine.
[13] M. Lehtinen,et al. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Vittorio Krogh,et al. Circulating Inflammation Markers and Risk of Epithelial Ovarian Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[15] Richard D Riley,et al. Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.
[16] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[17] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[18] S. Bojesen,et al. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Berrino,et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy) , 2009, Cancer Causes & Control.
[20] Anil K Sood,et al. Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Brinton,et al. C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk , 2007, Obstetrics and gynecology.
[22] T. Hagemann,et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.
[23] J. Ferlay,et al. Worldwide burden of gynaecological cancer: the size of the problem. , 2006, Best practice & research. Clinical obstetrics & gynaecology.
[24] A. Trichopoulou,et al. Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from Greece , 2006, Cancer Epidemiology Biomarkers & Prevention.
[25] J. Manson,et al. Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.
[26] P. Schwartz. Diagnosis and treatment of epithelial ovarian cancer. , 2003, Minerva ginecologica.
[27] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[28] R. Tweedie,et al. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis , 2000 .
[29] R. Ness,et al. Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.
[30] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[31] G. Mantovani,et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. , 1998, Gynecologic oncology.
[32] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[33] G. Mantovani,et al. Preovulatory human follicular fluid in vitro inhibits interleukin (IL)-1 alpha, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes. , 1994, Fertility and sterility.
[34] L. Twiggs,et al. Serum and ascitic fluid levels of interleukin‐1, interleukin‐6, and tumor necrosis factor‐alpha in patients with ovarian epithelial cancer , 1993, Cancer.
[35] S. Greenland,et al. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. , 1992, American journal of epidemiology.
[36] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[37] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[38] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.